Published in Vaccine on September 15, 2008
Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine (2012) 1.08
Systematic review of model-based cervical screening evaluations. BMC Cancer (2015) 0.98
Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program. Milbank Q (2014) 0.95
A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health (2010) 0.90
Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health (2011) 0.85
Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections. Cancer Med (2015) 0.81
Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control. J Cancer Epidemiol (2011) 0.80
Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. Br J Cancer (2010) 0.79
Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. BMC Public Health (2014) 0.77
Modeling optimal cervical cancer prevention strategies in Nigeria. BMC Cancer (2014) 0.76
Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada. BMC Public Health (2012) 0.76
Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach. PLoS One (2016) 0.75
Management strategies and cost effectiveness in the prevention of cervical cancer. Clinicoecon Outcomes Res (2009) 0.75
Economic evaluations of vaccines in Canada: a scoping review. Cost Eff Resour Alloc (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS (2008) 4.21
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Parents' health beliefs and HPV vaccination of their adolescent daughters. Soc Sci Med (2009) 4.12
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst (2012) 3.87
Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev (2005) 3.40
Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis (2011) 3.39
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa. J Low Genit Tract Dis (2015) 3.30
The epidemiology of genital human papillomavirus infection. Vaccine (2006) 3.28
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.25
Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis (2011) 3.16
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09
Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol Biomarkers Prev (2009) 3.07
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine (2006) 2.95
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91
Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol (2007) 2.90
Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer (2009) 2.90
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82
Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75
HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev (2008) 2.57
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol (2007) 2.49
Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2006) 2.39
Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med (2007) 2.35
2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol (2012) 2.32
The disparity of cervical cancer in diverse populations. Gynecol Oncol (2008) 2.27
Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis (2005) 2.20
Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol (2006) 2.20
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ (2010) 2.10
Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int (2004) 2.09
The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis (2005) 2.07
The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol (2003) 2.04
HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol (2006) 2.03
HPV vaccine acceptability in a rural Southern area. J Womens Health (Larchmt) (2008) 2.02
Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00
Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control (2003) 2.00
Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer (2002) 1.98
Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr Blood Cancer (2008) 1.98
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96
HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis (2011) 1.95
Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis (2003) 1.93
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92
Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control (2008) 1.89
Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis (2009) 1.89
Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med (2011) 1.89
Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health (2009) 1.86
Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst (2012) 1.86
Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev (2010) 1.85
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst (2003) 1.84
Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One (2013) 1.83
Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer (2007) 1.82
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78
Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer (2003) 1.78
Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77
Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer (2003) 1.77
Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health (2008) 1.76
Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer (2003) 1.74
Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses. Int J Epidemiol (2004) 1.73
Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis (2008) 1.72
High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer (2012) 1.71
Human papillomavirus infection among women in South and North Vietnam. Int J Cancer (2003) 1.71
Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev (2005) 1.71